Earnings Call · Q2 FY2026·2026-08-06

Q2 26EPS -100.00%*·Rev n/aQ1 26EPS +61.90%·Rev n/aQ4 25EPS -100.00%*·Rev n/aQ3 25EPS +9.09%·Rev n/a⚠ consensus missing

Tarsus Pharmaceuticals, Inc. TARS

Sarah Knives — Investor Relations

Bobak Azamian — Chief Executive Officer and Chairman

Neera Klase — Interim Chief Commercial Officer

Seshadri Neervannan — Chief Operating Officer

Jeff Farrow — Chief Financial Officer and Chief Strategy Officer

+6.6%1d on move date3d+10.6%5d+14.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TARS calls or request research access.

More TARS calls Browse calls Request research access